Farma

stockwalker
09.04.2021 kl 12:19 5418

CEO launchet viktige Roche medisiner, men for å pirke står det ikke her direkte referansen til Rituximab..

AGM, s 18
New CEO appointed to drive regulatory and commercialisation strategy
Moving forward, I am delighted with the very recent appointment of Peter Braun as our new CEO. Peter brings extensive commercial leadership experience from a nearly 30-year career at Roche, during which he led the Lifecycle Management teams for the successful targeted cancer therapies Herceptin® (trastuzumab) and Tarceva® (erlotinib). In addition, Peter held a number of operational roles, including affiliate General Manager roles. Peter is expected to play a key role in refining and driving the company’s plans towards the regulatory filing and commercialisation of Betalutin®.
Redigert 09.04.2021 kl 12:35

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.